## Antimalarial Treatment Guidelines Under NVBDCP **Key Point:** Artemisinin-based combination therapies (ACTs) are the gold standard first-line treatment for uncomplicated P. falciparum malaria across India, as per NVBDCP guidelines aligned with WHO recommendations. ### Current NVBDCP Recommendation Artemether-lumefantrine (or artesunate-amodiaquine) is the recommended first-line ACT for: - Uncomplicated P. falciparum malaria - Mixed species infections - Areas with confirmed artemisinin resistance (though still rare in India) **High-Yield:** ACTs work through rapid parasite clearance (artemisinin component) followed by sustained suppression (partner drug), reducing gametocyte carriage and transmission. ### Why ACTs Over Monotherapy? | Feature | ACT (Artemether-Lumefantrine) | Chloroquine Monotherapy | |---------|-------------------------------|------------------------| | Efficacy vs P. falciparum | >95% | <50% (widespread resistance) | | Parasite clearance time | 3–5 days | 7+ days | | Gametocyte reduction | Excellent | Poor | | Resistance risk | Minimal | High | **Clinical Pearl:** Chloroquine resistance in P. falciparum emerged in the 1950s–60s and is now ubiquitous in India; monotherapy is no longer acceptable for falciparum malaria. **Mnemonic:** ACT = **A**rtemisinin **C**ombination **T**herapy — always use two drugs to prevent resistance and ensure rapid cure. [cite:Park 26e Ch Communicable Diseases]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.